leadf
logo-loader
viewOpen Orphan PLC
(
AIM:ORPHFRA:CRO
)

Open Orphan first half: 'period of integration, restructuring and setting the scene' for future growth

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year. 

In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in January.

The company reported £7.1mln of H1 2020 revenues on a reported basis, (no comparable revenues in H1 2019).

Click here to read Emma Ulker's latest research update

Quick facts: Open Orphan PLC

Follow
AIM:ORPH

Price: 24.75 GBX

Market Cap: £166.04 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

FOR OUR FULL DISCLAIMER CLICK HERE

Open Orphan: New deal with top-three pharma company is 'evidence validation...

Proactive Research analyst Emma Ulker says the news this morning that Open Orphan PLC (LON:ORPH) subsidiary hVIVO has signed a £4mln contract with an unnamed top-three global pharma company is evidence that the validation is building as well as recognition amongst larger players in the industry....

on 10/8/20

2 min read